Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Emerging Biotech & Pharma Index: 36 More Cos.
Nov 24, 2008 01:40 AM
- Updated FDA Calendar Of 73 Decision Dates
Nov 22, 2008 12:57 PM
- A Backlog Of Decisions Is Building At The FDA
Nov 07, 2008 11:48 AM
- FDA Stings Pharma Big and Small
Jun 23, 2008 12:02 PM
- FDA Panel Backs Glaxo Platelet Drug For Short-Term Treatment
May 30, 2008 01:23 PM
- FDA Panel Backs Glaxo Platelet Drug For Short-Term Treatment
May 30, 2008 01:23 PM
- Glaxo Promacta Doesn't Significantly Cut Bleeding -FDA Staff
May 28, 2008 10:10 AM
- NASDAQ Technical Picture - Expansion
May 02, 2008 02:01 AM
- NASDAQ Technical Picture - Lower Trendline Holding
Feb 21, 2008 08:53 AM
- Future Of Cholesterol Drugs Put To Test At Heart Meeting
Mar 21, 2007 06:45 AM
- Ligand Collaborator GlaxoSmithKline Receives FDA Approval for PROMACTA®
Nov 20, 2008 07:04 PM
- Ligand Pharmaceuticals Announces Third Quarter Results
Nov 06, 2008 04:29 PM
- Ligand and Pharmacopeia to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Nov 04, 2008 07:30 AM
- Ligand to Hold Third Quarter Results Conference Call on November 6
Oct 28, 2008 04:17 PM
- Ligand and Pharmacopeia to Present At the Oppenheimer 19th Annual Healthcare Conference
Oct 28, 2008 04:01 PM
- Ligand to Acquire Pharmacopeia for Stock and Contingent Value Rights
Sep 24, 2008 06:01 PM
- Ligand to Acquire Pharmacopeia for Stock and Contingent Value Rights
Sep 24, 2008 05:11 PM
- Beacon Equity Issues Technical Trade Alerts on Market Movers: GSAE, THMD, AKSN, LGND, CRAY, DAL
Sep 17, 2008 09:02 AM
- Ligand Pharmaceuticals and the SALK Institute Enter Settlement Agreement and Mutual Release of All Claims
Sep 05, 2008 09:10 AM
- Ligand Pharmaceuticals Appoints Dr. Stephen Sabba to Board of Directors
Aug 04, 2008 04:10 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
LGND
|
Compare to S&P
|
| YTD |
-59.21 %
|
-0.01 %
|
| 4 Weeks |
3.68 %
|
22.85 %
|
| 12 Weeks |
-41.37 %
|
-15.42 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -100.00 %
|
|
EPS Growth in Last Year: -100.00 %
|
|
Sales Growth in Last Quarter: 9.24 %
|
|
Sales Growth in Last Quarter: -4.22 %
|
|
|
